MARKET

BGNE

BGNE

BeiGene
NASDAQ

Real-time Quotes | Nasdaq Last Sale

204.10
+7.51
+3.82%
Pre Market 05:04 07/09 EDT
OPEN
199.12
PREV CLOSE
196.59
HIGH
204.29
LOW
195.98
VOLUME
254.19K
TURNOVER
--
52 WEEK HIGH
210.35
52 WEEK LOW
114.41
MARKET CAP
15.87B
P/E (TTM)
-10.9225
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 15 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average BGNE stock price target is 199.40 with a high estimate of 232.00 and a low estimate of 165.00.

EPS

BGNE News

More
Is BeiGene, Ltd. (BGNE) A Good Stock To Buy?
Insider Monkey · 3d ago
iTeos Therapeutics Begins U.S. IPO Rollout
Seeking Alpha - Article · 6d ago
The Daily Biotech Pulse: Novartis Settles Lawsuit For $678M, Sarepta In-Licenses Gene Therapy Pre-Treatment, Unity Biotech Outlines Second-Half Catalysts
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 1)
Benzinga · 6d ago
BeiGene to Host Investor Conference Call and Webcast to Discuss the Companys Early Development Pipeline and Research
GlobeNewswire · 6d ago
BeiGene's application for tislelizumab accepted in China for liver cancer
Seeking Alpha - Article · 07/02 11:09
BeiGene Reports FDA Accepted Supplemental New Drug Application For Tislelizumab In Patients With Previously Treated Unresectable Hepatocellular Carcinoma In China
Benzinga · 07/01 22:01
BeiGene Announces Acceptance of a Supplemental New Drug Application for Tislelizumab in Patients with Previously Treated Unresectable Hepatocellular Carcinoma in China
BEIJING, China and CAMBRIDGE, Mass., July 01, 2020 -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and.
GlobeNewswire · 07/01 22:00
BeiGene Announces Appointment of Angus Grant as Chief Business Executive
GlobeNewswire · 07/01 12:00

Industry

Biotechnology & Medical Research
+1.13%
Pharmaceuticals & Medical Research
+0.50%

Hot Stocks

Symbol
Price
%Change

About BGNE

BeiGene, Ltd. is principally engaged in biopharmaceutical business. The Company is mainly engaged in the research and development, production and sales of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company's main products include Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317) and Pamiparib (BGB-290).
More

Webull offers kinds of Beigene Ltd (ADR) stock information, including NASDAQ:BGNE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BGNE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BGNE stock methods without spending real money on the virtual paper trading platform.